HealthQuill Fast Track Approval
AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to an antibody being tested for certain types of cancers and autoimmune conditions.
Drugs Health Pharma

AbbVie inks $2 billion deal with IGI, bags antibody to fight cancer 

HQ Team July 10, 2025: AbbVie Inc. and IGI Therapeutics SA have signed a $2 billion licensing agreement that gives AbbVie access to.

Read More
SAB Biotherapeutics got a fast-track designation from the USFDA for its investigational drug to treat influenza in high-risk and immunocompromised patients.
Drugs Medical Pharma

SAB gets FDA fast track nod for experimental drug to treat influenza

HQ Team April 14, 2023: SAB Biotherapeutics got a fast-track designation from the USFDA for its investigational drug to treat influenza in high-risk.

Read More